Profile of Neuropsychiatric Symptoms in Parkinson's Disease: Surgical Candidates Compared to Controls

Journal of Parkinson's Disease

Volumn 6, Issue 1, 2016, Pages 133-142

  Lamberti, Valérie M J ^a,b   Pereira, Bruno ^c   Lhommée, Eugénie ^a,d,e   Bichon, Amélie ^a,d,e   Schmitt, Emmanuelle ^a,d,e   Pelissier, Pierre ^a,d,e   Kistner, Andrea ^a,d,e   Fraix, Valérie ^a,d,e   Castrioto, Anna ^a,d,e   Esselink, Rianne A J ^b   Durif, Frank ^f   Krack, Paul ^a,d,e  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b RADBOUD UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d UNIV GRENOBLE ALPES   (France)

^e INSERM   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

Author keywords

deep brain stimulation; dopamine; impulse control disorders; Parkinson disease; subthalamic nucleus

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DEPENDENCE; FEMALE; HUMAN; HYPERACTIVITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARKINSON DISEASE; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; COMPARATIVE STUDY; PSYCHOLOGY;

COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEEP BRAIN STIMULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 85016337633     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-150698     Document Type: Article

References (51)

1. Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, & Hawkins KA (2015) Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord, 30, 919-927.
2. Sierra M, Carnicella S, Strafella AP, Bichon A, Lhommee E, Castrioto A, Chabardes S, Thobois S, & Krack P (2015) Apathy and impulsive control disorders: Yin & yang of dopamine dependent behaviors. J Parkinsons Dis, 5, 625-636.
3. Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, Ardouin C, Chereau I, Brefel-Courbon C, Ory-Magne F, Klinger H, Peyrol F, Schupbach M, Dujardin K, Tison F, Houeto JL, Krack P, & Durif F (2015) International validation of a behavioral scale in Parkinson's disease without dementia. Mov Disord, 30, 705-713.
4. Lhommee E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, Kistner A, Fraix V, Xie J, Aya Kombo M, Chabardes S, Seigneuret E, Benabid AL, Mertens P, Polo G, Carnicella S, Quesada JL, Bosson JL, Broussolle E, Pollak P, & Krack P (2012) Subthalamic stimulation in Parkinson'sdisease: Restoring the balance of motivated behaviours. Brain, 135, 1463-1477.
5. Ardouin C, Chereau I, Llorca PM, Lhommee E, Durif F, Pollak P, & Krack P (2009) [Assessment of hyper-and hypodopaminergic behaviors in Parkinson's disease]. Rev Neurol (Paris), 165, 845-856.
6. Antonelli F, & Strafella AP (2014) Behavioral disorders in Parkinson's disease: The role of dopamine. Parkinsonism Relat Disord, 20 (Suppl 1), S10-S12.
7. Vriend C, Pattij T, van der Werf YD, Voorn P, Booij J, Rutten S, Berendse HW, & van den Heuvel OA (2014) Depression and impulse control disorders in Parkinson's disease: Two sides of the same coin? Neurosci Biobehav Rev, 38, 60-71.
8. Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, & Krack P (2010) Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: Predictors and underlying mesolimbic denervation. Brain, 133, 1111-1127.
9. Duncan GW, Khoo TK, Yarnall AJ, O'Brien JT, Coleman SY, Brooks DJ, Barker RA, & Burn DJ (2014) Health-related quality of life in early Parkinson's disease: The impact of nonmotor symptoms. Mov Disord, 29, 195-202.
10. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, Barker RA, & Burn DJ (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology, 80, 276-281.
11. Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, & Larsen JP (2009) The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry, 80, 928-930.
12. Cubo E, Benito-Leon J, Coronell C, & Armesto D (2012) Clinical correlates of apathy in patients recently diagnosed with Parkinson's disease: The ANIMO study. Neuroepidemiology, 38, 48-55.
13. Rabinak CA, & Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol, 67, 58-63.
14. Reijnders JS, Ehrt U, Weber WE, Aarsland D, & Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord, 313, 183-189; quiz, 313.
15. Gallagher DA, & Schrag A (2012) Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis, 46, 581-589.
16. Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, & Svenningsson P (2012) Depression in Parkinson disease-epidemiology, mechanisms and management. Nature reviews. Neurology, 8, 35-47.
17. Pagonabarraga J, Kulisevsky J, Strafella AP, & Krack P (2015) Apathy in Parkinson's disease: Clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol, 14, 518-531.
18. Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A, Kistner A, Castrioto A, Xie J, Fraix V, Pelissier P, Chabardes S, Mertens P, Quesada JL, Bosson JL, Pollak P, Broussolle E, & Krack P (2013) Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain, 136, 1568-1577.
19. Czernecki V, Schupbach M, Yaici S, Levy R, Bardinet E, Yelnik J, Dubois B, & Agid Y (2008) Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom. Mov Disord, 23, 964-969.
20. Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, & Lang AE (2015) Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Mov Disord, 30, 150-159.
21. Maricle RA, Nutt JG, Valentine RJ, & Carter JH (1995) Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study. Neurology, 45, 1757-1760.
22. Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, Tezenas du Moncel S, Bonnet AM, Pidoux B, Dormont D, Cornu P, & Agid Y (2002) Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry, 72, 701-707.
23. Krack P, Kumar R, Ardouin C, Dowsey PL, McVicker JM, Benabid AL, & Pollak P (2001) Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord, 16, 867-875.
24. Kulisevsky J, Berthier ML, Gironell A, Pascual-Sedano B, Molet J, & Par SP (2002) Mania following deep brain stimulation for Parkinson's disease. Neurology, 59, 1421-1424.
25. Mandat TS, Hurwitz T, & Honey CR (2006) Hypomania as an adverse effect of subthalamic nucleus stimulation: Report of two cases. Acta Neurochir (Wien), 148, 895-897; discussion, 898.
26. Raucher-Chene D, Charrel CL, de Maindreville AD, & Limosin F (2008) Manic episode with psychotic symptoms in a patient with Parkinson's disease treated by subthalamic nucleus stimulation: Improvement on switching the target. J Neurol Sci, 273, 116-117.
27. Eusebio A, Witjas T, Cohen J, Fluchere F, Jouve E, Regis J, & Azulay JP (2013) Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry, 84, 868-874.
28. Okun MS, & Weintraub D (2013) Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? Mov Disord, 28, 1915-1919.
29. Weintraub D, David AS, Evans AH, Grant JE, & Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord, 30, 121-127.
30. Mattis S. (1988) Dementia Rating Scale: Professional Manual, Psychological Assessment Resources Inc, Odessa, FL.
31. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, & Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med, 349, 1925-1934.
32. Beck AT, Steer RA, Ball R, & Ranieri W (1996) Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess, 67, 588-597.
33. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, & Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci, 4, 134-139.
34. Montgomery SA, & Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry, 134, 382-389.
35. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, & Defebvre L (2006) The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: Validation in Parkinson's disease. J Neurol Neurosurg Psychiatry, 77, 579-584.
36. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, & Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord, 25, 2649-2653.
37. Nutt J, & Holford NHG (1996) The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann Neurol, 39, 561-573.
38. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, & Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry, 68, 423-428.
39. Lawrence AD, Evans AH, & Lees AJ (2003) Compulsive use of dopamine replacement therapy in Parkinson's disease: Reward systems gone awry? Lancet Neurol, 2, 595-604.
40. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, & Lang AE (2010) Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol, 67, 589-595.
41. Kistner A, Lhommee E, & Krack P (2014) Mechanisms of body weight fluctuations in Parkinson's disease. Front Neurol, 5, 84.
42. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, & Weintraub D (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol, 9, 573-580.
43. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, & Goetz CG (2008) Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations. Mov Disord, 23, 2004-2014.
44. Schrag A, & Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol, 5, 355-363.
45. Lim SY, O'Sullivan SS, Kotschet K, Gallagher DA, Lacey C, Lawrence AD, Lees AJ, O'Sullivan DJ, Peppard RF, Rodrigues JP, Schrag A, Silberstein P, Tisch S, & Evans AH (2009) Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci, 16, 1148-1152.
46. Martinez-Fernandez R, Pelissier P, Quesada JL, Klinger H, Lhommée E, Schmitt E, Fraix V, Chabardès S, Mertens P, Castrioto A, Kistner A, Broussolle E, Pollak P, Thobois S, Krack P (2015) Postoperative apathy can neutralize benefits in quality of life after subthalamic stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry, doi: 10.1136/jnnp-2014-310189
47. Castrioto A, Kistner A, Klinger H, Lhommee E, Schmitt E, Fraix V, Chabardes S, Mertens P, Quesada JL, Broussolle E, Pollak P, Thobois SC, & Krack P (2013) Psychostimulant effect of levodopa: Reversing sensitisation is possible. J Neurol Neurosurg Psychiatry, 84, 18-22.
48. Schrag A (2006) Quality of life and depression in Parkinson's disease. J Neurol Sci, 248, 151-157.
49. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, & Dotto PD (2009) The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord, 24, 1641-1649.
50. Kim SR, So HY, Choi E, Kang JH, Kim HY, & Chung SJ (2014) Influencing effect of non-motor symptom clusters on quality of life in Parkinson's disease. J Neurol Sci, 347, 310-315.
51. Hack N, Akbar U, Thompson-Avila A, Fayad SM, Hastings EM, Moro E, Nestor K, Ward H, York M, & Okun MS (2014) Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery. J Parkinsons Dis, 4, 591-598.